Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: Findings from routine clinical practice.

{ 'indexed': {'date-parts': [[2023, 8, 10]], 'date-time': '2023-08-10T04:31:13Z', 'timestamp': 1691641873145}, 'reference-count': 0, 'publisher': 'Oxford University Press (OUP)', 'license': [ { 'start': { 'date-parts': [[2023, 8, 9]], 'date-time': '2023-08-09T00:00:00Z', 'timestamp': 1691539200000}, 'content-version': 'am', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>Immunocompromised patients are at high risk of severe COVID-19 and ' 'death, yet treatment strategies for immunocompromised patients hospitalized for COVID-19 ' 'reflect variations in clinical practice. This comparative effectiveness study investigated ' 'the effect of remdesivir treatment on inpatient mortality among immunocompromised patients ' 'hospitalized for COVID-19 across all variants of concern (VOC) periods.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>Data for immunocompromised patients hospitalized for COVID-19 ' 'between December 2020 and April 2022 were extracted from the US PINC AI Healthcare Database. ' 'Patients initiating remdesivir within two days of hospitalization were matched 1:1 using ' 'propensity score matching with replacement to patients who did not receive remdesivir during ' 'their hospitalization for COVID-19. Additional matching criteria included admission month, ' 'age group, and hospital. Cox Proportional Hazards models were used to examine the effect of ' 'remdesivir on risk of 14- and 28-day mortality during VOC periods.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>A total of 19,184 remdesivir patients were matched to 11,213 ' 'non-remdesivir patients. Overall, 11.1% and 17.7% of remdesivir patients died within 14 and ' '28 days, respectively, compared with 15.4% and 22.4% of non-remdesivir patients. Remdesivir ' 'was associated with a reduction in mortality at 14 days (hazard ratio [95% confidence ' 'interval]: 0.70 [0.62–0.78]) and 28 days (0.75 [0.68–0.83]). Survival benefit remained ' 'significant during the Pre-Delta, Delta, and Omicron time-periods.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>Prompt initiation of remdesivir in immunocompromised patients ' 'hospitalized for COVID-19 is associated with significant survival benefit across all variant ' 'waves. These findings provide much-needed evidence relating to the effectiveness of a ' 'foundational treatment for hospitalized COVID-19 patients among a high-risk ' 'population.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/cid/ciad460', 'type': 'journal-article', 'created': {'date-parts': [[2023, 8, 8]], 'date-time': '2023-08-08T04:31:21Z', 'timestamp': 1691469081000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across ' 'variant waves: Findings from routine clinical practice.', 'prefix': '10.1093', 'author': [ { 'given': 'Essy', 'family': 'Mozaffari', 'sequence': 'first', 'affiliation': [{'name': 'Gilead Sciences, Foster City , California , USA'}]}, { 'given': 'Aastha', 'family': 'Chandak', 'sequence': 'additional', 'affiliation': [{'name': 'Certara, New York , New York , USA'}]}, { 'given': 'Robert L', 'family': 'Gottlieb', 'sequence': 'additional', 'affiliation': [ {'name': 'Baylor University Medical Center , Dallas, Texas , USA'}, { 'name': 'Baylor Scott & White Heart and Vascular Hospital , Dallas, Texas ' ', USA'}, {'name': 'Baylor Scott & White The Heart Hospital , Plano, Texas , USA'}, {'name': 'Baylor Scott & White Research Institute , Dallas, Texas , USA'}]}, { 'given': 'Chidinma', 'family': 'Chima-Melton', 'sequence': 'additional', 'affiliation': [{'name': 'UCLA Health , Torrance, California , USA'}]}, { 'given': 'Stephanie H', 'family': 'Read', 'sequence': 'additional', 'affiliation': [{'name': 'Certara , London , United Kingdom'}]}, { 'given': 'Heng', 'family': 'Jiang', 'sequence': 'additional', 'affiliation': [{'name': 'Certara , Paris , France'}]}, { 'given': 'Mel', 'family': 'Chiang', 'sequence': 'additional', 'affiliation': [{'name': 'Gilead Sciences, Foster City , California , USA'}]}, { 'given': 'EunYoung', 'family': 'Lee', 'sequence': 'additional', 'affiliation': [{'name': 'Gilead Sciences, Foster City , California , USA'}]}, { 'given': 'Rikisha', 'family': 'Gupta', 'sequence': 'additional', 'affiliation': [{'name': 'Gilead Sciences, Foster City , California , USA'}]}, { 'given': 'Mark', 'family': 'Berry', 'sequence': 'additional', 'affiliation': [{'name': 'Gilead Sciences, Foster City , California , USA'}]}, { 'ORCID': 'http://orcid.org/0000-0002-6489-6294', 'authenticated-orcid': False, 'given': 'Andre C', 'family': 'Kalil', 'sequence': 'additional', 'affiliation': [{'name': 'University of Nebraska Medical Center , Omaha, Nebraska , USA'}]}], 'member': '286', 'published-online': {'date-parts': [[2023, 8, 9]]}, 'container-title': 'Clinical Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad460/51077887/ciad460.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad460/51077887/ciad460.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 8, 9]], 'date-time': '2023-08-09T18:52:17Z', 'timestamp': 1691607137000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad460/7240094'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 8, 9]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1093/cid/ciad460', 'relation': {}, 'ISSN': ['1058-4838', '1537-6591'], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'published': {'date-parts': [[2023, 8, 9]]}}